{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:23:04Z","timestamp":1778494984888,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clear cell carcinoma is an uncommon histologic subtype of ovarian and endometrial carcinoma with poor response to Platinium-based chemotherapy agents at high stages. Blockage of Programmed cell Death Ligand-1 (PD-L1), can be used in targeted immunotherapy. This study investigated Mismatch Repair Deficiency (MMR-D) status, PD-L1 expression, and the correlation between PD-L1 expression and microsatellite instability (MSI) status in ovarian and endometrial clear cell carcinomas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ovarian clear cell carcinoma (OCCC) (<jats:italic>n<\/jats:italic>\u2009=\u200928) and endometrial clear cell carcinoma (ECCC) (<jats:italic>n<\/jats:italic>\u2009=\u200928) samples were evaluated for PD-L1 (in tumoral and peri-tumoral inflammatory cells), MSH6 and PMS2 expression by immunohistochemistry (IHC) study. PD-L1 expression\u2009&gt;\u20091% in tumor cells and\u2009&gt;\u20095% in peritumoral inflammatory cells were considered positive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of PD-L1 expression was higher in ECCC (20\/28, 71.43%) compared to OCCC tumor cells (16\/28, 57.15%) (p\u2009&gt;\u20090.05), while expression in peritumoral inflammatory cells was significantly higher in ECCC (25\/28, 89.29%) compared to OCCC (11\/28, 39.28%) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). MMR-D was observed in 5 cases, four OCCCs and one ECCC, among which, four (80%) showed PD-L1 expression in peritumoral inflammatory and tumor cells. The only OCCC case with extensive PD-L1 expression in tumor cells (&gt;\u200950%) exhibited MSH6\/MSH2 loss. No significant correlation was noted between PD-L1 expression and the pathologic stage or survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PD-L1 expression was significantly associated with clear cell morphology, especially in the endometrium, independent of MMR protein status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10478-7","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T22:02:32Z","timestamp":1672351352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Dorsa","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Ameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Nili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramtin","family":"Edjtemaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Sheikhhasani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"6","key":"10478_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00428-020-02867-9","volume":"477","author":"G Kir","year":"2020","unstructured":"Kir G, Soylemez T, Olgun ZC, Aydin A, McCluggage WG. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas. Virchows Arch. 2020;477(6):845\u201356.","journal-title":"Virchows Arch"},{"issue":"4","key":"10478_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ijgc-2020-001656","volume":"31","author":"Y Iida","year":"2021","unstructured":"Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021;31(4):605\u201316.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10478_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-021-00804-1","volume":"14","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yao L, Dai L, Zhu H, Ye X, Wang S, et al. Ovarian endometrioid carcinoma and clear cell carcinoma: a 21-year retrospective study. J Ovarian Res. 2021;14(1):1\u201312.","journal-title":"J Ovarian Res"},{"issue":"4","key":"10478_CR4","first-page":"1327","volume":"30","author":"A Gadducci","year":"2010","unstructured":"Gadducci A, Cosio S, Spirito N, Cionini L. Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res. 2010;30(4):1327\u201334.","journal-title":"Anticancer Res"},{"issue":"5","key":"10478_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","volume":"94","author":"C Hamilton","year":"2006","unstructured":"Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642\u20136.","journal-title":"Br J Cancer"},{"key":"10478_CR6","doi-asserted-by":"publisher","unstructured":"Zhang Z, Gao P, Zeng L, Yao J, Chai D, Li T. Clear cell carcinoma of the endometrium: evaluation of prognostic parameters in 27 cases. Front Oncol. 2021;11:732782. https:\/\/doi.org\/10.3389\/fonc.2021.732782.","DOI":"10.3389\/fonc.2021.732782"},{"key":"10478_CR7","doi-asserted-by":"publisher","first-page":"i50","DOI":"10.1093\/annonc\/mdw086","volume":"27","author":"K Fujiwara","year":"2016","unstructured":"Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol. 2016;27:i50\u20132.","journal-title":"Ann Oncol"},{"issue":"3","key":"10478_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","volume":"126","author":"MG Del Carmen","year":"2012","unstructured":"Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126(3):481\u201390.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10478_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2017.11.020","volume":"148","author":"R Murali","year":"2018","unstructured":"Murali R, Grisham RN, Soslow RA. The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecol Oncol. 2018;148(1):213\u201321.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10478_CR10","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3802\/jgo.2016.27.e31","volume":"27","author":"S Mabuchi","year":"2016","unstructured":"Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27(3):e31.","journal-title":"J Gynecol Oncol"},{"issue":"19","key":"10478_CR11","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10478_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10147-016-0958-0","volume":"21","author":"S Chikuma","year":"2016","unstructured":"Chikuma S. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016;21(3):448\u201355.","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10478_CR13","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/modpathol.2017.67","volume":"30","author":"BC Willis","year":"2017","unstructured":"Willis BC, Sloan EA, Atkins KA, Stoler MH, Mills AM. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol. 2017;30(11):1622\u201332.","journal-title":"Mod Pathol"},{"issue":"5","key":"10478_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.21037\/tcr.2018.10.11","volume":"7","author":"B-H Cheng","year":"2018","unstructured":"Cheng B-H, Liang H, Jiang T, Chen J-H, Wang G-H. Characterization of PD-L1 expression and its prognostic value in patients with ovarian cancer. Transl Cancer Res. 2018;7(5):1271\u201381.","journal-title":"Transl Cancer Res"},{"key":"10478_CR15","doi-asserted-by":"publisher","unstructured":"Lorenzi M, Amonkar M, Zhang J, Mehta S, Liaw K-L. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020;2020(1807929):17. https:\/\/doi.org\/10.1155\/2020\/1807929.","DOI":"10.1155\/2020\/1807929"},{"issue":"1","key":"10478_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ygyno.2014.07.100","volume":"135","author":"KR Vierkoetter","year":"2014","unstructured":"Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014;135(1):81\u20134.","journal-title":"Gynecol Oncol"},{"key":"10478_CR17","doi-asserted-by":"publisher","first-page":"666815","DOI":"10.3389\/fonc.2021.666815","volume":"11","author":"OG Wong","year":"2021","unstructured":"Wong OG, Li J, Cheung AN. Targeting DNA damage response pathway in ovarian clear cell carcinoma. Front Oncol. 2021;11:666815.","journal-title":"Front Oncol"},{"issue":"1","key":"10478_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1066896919862618","volume":"28","author":"C Jin","year":"2020","unstructured":"Jin C, Hacking S, Liang S, Nasim M. PD-L1\/PD-1 expression in endometrial clear cell carcinoma: a potential surrogate marker for clinical trials. Int J Surg Pathol. 2020;28(1):31\u20137.","journal-title":"Int J Surg Pathol"},{"key":"10478_CR19","unstructured":"WHO classification of female genital tract tumors2020. 5 ed. WHO Classification of Tumours, ed. W.C.o.T.E. Board. World Health Organization: International Agency for Research on Cancer. 2020;4:631."},{"key":"10478_CR20","unstructured":"College of american pathologists protocols. 2022."},{"issue":"1","key":"10478_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0738-1","volume":"12","author":"P Zhao","year":"2019","unstructured":"Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10478_CR22","doi-asserted-by":"publisher","first-page":"e1277308","DOI":"10.1080\/2162402X.2016.1277308","volume":"6","author":"BE Howitt","year":"2017","unstructured":"Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, et al. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression. Oncoimmunology. 2017;6(2):e1277308.","journal-title":"Oncoimmunology"},{"key":"10478_CR23","doi-asserted-by":"crossref","unstructured":"Matsuura H, Miyamoto M, Hada T, Ishibashi H, Iwahashi H, Kakimoto S, et al. The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. Arch Gynecol Obstetr. 2022. pp. 1\u201310.","DOI":"10.1007\/s00404-022-06582-5"},{"issue":"3","key":"10478_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2019.10.008","volume":"155","author":"J Alldredge","year":"2019","unstructured":"Alldredge J, Serna-Gallegos T, Gallegos N, VanLeer JP, Chang J, Ziogas A, et al. Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival. Gynecol Oncol. 2019;155(3):483\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10478_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/PAS.0000000000000783","volume":"41","author":"EA Sloan","year":"2017","unstructured":"Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM. PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including Lynch syndrome-associated and MLH1 promoter hypermethylated tumors. Am J Surg Pathol. 2017;41(3):326\u201333.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10478_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","volume":"151","author":"K Oda","year":"2018","unstructured":"Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management. Gynecol Oncol. 2018;151(2):381\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10478_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-019-0512-6","volume":"12","author":"L Wang","year":"2019","unstructured":"Wang L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study. J Ovarian Res. 2019;12(1):1\u201310.","journal-title":"J Ovarian Res"},{"issue":"6","key":"10478_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/PGP.0000000000000750","volume":"40","author":"G Kir","year":"2021","unstructured":"Kir G, Olgun ZC, Soylemez T, Aydin A, Demircan B, Kaya IA, et al. PD-L1 Expression in mismatch repair-deficient endometrial carcinoma and tumor-associated immune cells: differences between MLH1 methylated and nonmethylated subgroups. Int J Gynecol Pathol. 2021;40(6):575\u201386.","journal-title":"Int J Gynecol Pathol"},{"issue":"6","key":"10478_CR29","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.3802\/jgo.2017.28.e77","volume":"28","author":"J Zhu","year":"2017","unstructured":"Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017;28(6):e77.","journal-title":"J Gynecol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10478-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10478-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T22:02:36Z","timestamp":1672351356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10478-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10478"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10478-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"19 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental methods were approved in the local ethics committee of the Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (IR.TUMS.IKHC.REC.1399.445). All the methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all participants and\/or their legal guardian(s). Identifiable data of the participants has not been given in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1362"}}